CAH vs CLOV Stock Comparison
Compare CAH and CLOV across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between CAH and CLOV?
CAH leads the current stock comparison as Cardinal Health, Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Cardinal Health, Inc. vs Clover Health Investments, Corp.
CAH leads
CAH leads by 3 AIQ points, primarily on Risk Resilience and Value, but the lead has narrowed from 11 points over 30 sessions.
Fragile: 3 of 6 evidence groups support CAH, its lead is narrowing, and its current signal state is conflicted.
Cardinal Health, Inc.
Clover Health Investments, Corp.
The Algovestiq AIQ Score currently favors CAH over CLOV, 52 versus 49 as of Sep 11, 2026. CAH's advantage is driven primarily by stronger risk resilience and value, while CLOV holds the stronger momentum profile. CAH also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor CAH today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. CAH lead: Weakening — the AIQ differential moved from 11 to 3 points over 30 sessions.
Compare Cardinal Health, Inc. and Clover Health Investments, Corp. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare CAH and CLOV against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience55 vs 35CAH +20
- Value57 vs 42CAH +15
- Momentum69 vs 78CLOV +9
- Quality32 vs 38CLOV +6
3 of 6 evidence groups favor CAH. CAH’s edge is concentrated in risk resilience and value; CLOV keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +1
New signals
- MACD Bearish Crossover — bearish, momentum, short horizon
Largest factor move: Momentum +23
New signals
- BB Upper Band Breach — bearish, volatility, short horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
CAH's lead narrowed by 5 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — CAH and CLOV both carry a full feed there.
The central trade-off
CAH (Cardinal Health, Inc.): the stronger current systematic profile, led by risk resilience and value.
CLOV (Clover Health Investments, Corp.): the counter-case, on momentum, quality, technicals — but at materially higher volatility, 47.5% against 24.2%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
CAHCAH on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
CAHCAH on combined revenue and EPS growth.
Value
CAHCAH on the peer-relative Value factor, by 15 points.
Momentum
CLOVCLOV on the Momentum factor, by 9 points.
Lower downside
CAHCAH on Risk Resilience, by 20 points.
Analyst upside
CAHCAH on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | CAH | CLOV | Note |
|---|---|---|---|
| Implied upside to target | +14.4% | +0.8% | CAH has more room |
| Target dispersion | +19.4% | +26.7% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 9 | 2 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor CAH. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 52 vs 49 |
| Fundamentals | Even | EPS growth 1.2% vs -4.6%; TTM ROE -59.7% vs -5.4%; gross margin 3.8% vs 18.6%; operating margin 1% vs -0.7% |
| Valuation | CAH | Value 57 vs 42 |
| Technicals | CLOV | Price vs 50-day 0.1% vs 8.1%; vs 200-day 9.2% vs 48.5% |
| Risk Resilience | CAH | Risk Resilience 55 vs 35 |
| Analyst expectations | CAH | Target upside 14.4% vs 0.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of CAH and CLOV and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on CAH.
How the comparison changed
119 daily snapshots · May 4 – Sep 10CAH lead: Weakening — the AIQ differential moved from 11 to 3 points over 30 sessions.
- Today
- CAH +3
- 52 vs 49
- 7 sessions ago
- CAH +14
- 55 vs 41
- 30 sessions ago
- CAH +11
- 51 vs 40
- 90 sessions ago
- CAH +9
- 54 vs 45
The lead changed hands once in this window, most recently on May 20 when CAH moved ahead of CLOV.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (8.37%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
4 bullish / 2 bearish / 2 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (40.62%)
- BB Upper Band Breach — bearish, volatility, short horizon
- Keltner Channel Breakout — bullish, volatility, short horizon
CAH leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.61%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +2.34%, AIQ +5 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1CLOV closes the Risk Resilience gap — currently 20 points behind, the largest single contributor to CAH's edge.
- 2CLOV's BB Upper Band Breach resolves — a bearish volatility rule currently active against it.
- 3CAH's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 8 points over 30 sessions, and a further 3-point move would eliminate CAH's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | CAH | CLOV |
|---|---|---|
| Revenue growth (YoY) | 4.8% | -0.8% |
| EPS growth (YoY) | 1.2% | -4.6% |
| Gross margin | 3.8% | 18.6% |
| Operating margin | 1% | -0.7% |
| Return on equity (TTM) | -59.7% | -5.4% |
| Debt to equity | -3.45 | 0 |
Performance
CLOV leads 5 of 6 windows| Metric | CAH | CLOV |
|---|---|---|
| 1 week (5 sessions) | -3.9% | 9.5% |
| 1 month (20 sessions) | 0.8% | 3.7% |
| 3 months (63 sessions) | 9.1% | -3.7% |
| 6 months (126 sessions) | 9.6% | 128.7% |
| Year to date | 14.9% | 100.4% |
| 1 year (252 sessions) | 57.1% | 71.9% |
Technicals
CLOV has the stronger structure| Metric | CAH | CLOV |
|---|---|---|
| RSI (14) | 59.3 | 81.1 |
| ADX (14) | 27.8 | 11.3 |
| Price vs 50-day | 0.1% | 8.1% |
| Price vs 200-day | 9.2% | 48.5% |
| Volatility (1M, annualized) | 24.2% | 47.5% |
Risk
CAH is the more resilient| Metric | CAH | CLOV |
|---|---|---|
| Beta | -0.06 | 1.18 |
| Sharpe ratio | 1.51 | 1 |
| Sortino ratio | 2.72 | 1.8 |
| Max drawdown | -20.6% | -55.5% |
| Current drawdown | -5.1% | -12.9% |
| Annualized volatility | 30% | 67.3% |
| Value at risk (95%) | -2.5% | -4.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, CAH or CLOV?
On the Algovestiq AIQ Score, CAH is the stronger of the two as of Sep 11, 2026, scoring 52 against CLOV's 49. The edge comes from risk resilience and value. CLOV is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is CAH or CLOV the better buy right now?
CAH carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor CAH over CLOV?
The composite weights Quality, Value, Momentum and Risk Resilience. CAH leads Risk Resilience by 20 points; CAH leads Value by 15 points; CLOV leads Momentum by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, CAH or CLOV?
Analyst price targets imply +14.4% upside for CAH and +0.8% for CLOV, so the Street currently favors CAH. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, CAH or CLOV?
CAH is the better-valued of the two on the peer-relative Value factor. CAH on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, CAH or CLOV?
CAH on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, CAH or CLOV?
CLOV on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, CAH or CLOV?
CAH is the more resilient of the two, so the other name carries the higher downside risk. CAH on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is CAH more profitable than CLOV?
The profitability evidence is mixed: gross margin 3.8% vs 18.6%; operating margin 1% vs -0.7%; ttm roe -59.7% vs -5.4%. CAH leads on one measure and CLOV on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is CAH's lead over CLOV getting stronger or weaker?
CAH lead: Weakening — the AIQ differential moved from 11 to 3 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands once in that window, most recently on 2026-05-20, when CAH moved ahead of CLOV.
What would change the CAH vs CLOV verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: CLOV closes the Risk Resilience gap — currently 20 points behind, the largest single contributor to CAH's edge; CLOV's BB Upper Band Breach resolves — a bearish volatility rule currently active against it; CAH's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 8 points over 30 sessions, and a further 3-point move would eliminate CAH's advantage entirely.
What do the current signals say about CAH and CLOV?
CAH: 3 bullish / 1 bearish, conflicted. CLOV: 4 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on CAH is Golden Cross Active (bullish, long horizon). On CLOV it is Golden Cross Active (bullish, long horizon).
Compare CAH and CLOV with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.